Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Blog Pricing

Sam Fazeli

👤 Speaker
634 total appearances

Appearances Over Time

Podcast Appearances

Vanguards of Health Care by Bloomberg Intelligence
Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody Drug Conjugates

Looking also at Destiny Bristol 9, Destiny Bristol 3, it begins to cover a whole population almost of the patients.

Vanguards of Health Care by Bloomberg Intelligence
Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody Drug Conjugates

So do you want to tell us what we learned from DB11, just to shorten it, and what it means first for the DB11 and what it means for patients?

Vanguards of Health Care by Bloomberg Intelligence
Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody Drug Conjugates

Now, these are patients, as you rightly say, that are being treated with curative intent.

Vanguards of Health Care by Bloomberg Intelligence
Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody Drug Conjugates

Given that, how long do you think we'd have to wait to see if there's an impact on overall survival?

Vanguards of Health Care by Bloomberg Intelligence
Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody Drug Conjugates

You did say that pathologic complete response, which just to be clear, is when you take tumors out and have a look at them and you find no viable cells.

Vanguards of Health Care by Bloomberg Intelligence
Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody Drug Conjugates

There might be tumor there, but...

Vanguards of Health Care by Bloomberg Intelligence
Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody Drug Conjugates

or at least a mass there, but no viable cells or very few.

Vanguards of Health Care by Bloomberg Intelligence
Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody Drug Conjugates

How long would it take before we see whether there is a major or meaningful impact on survival here, which of course has to be the end game, right?

Vanguards of Health Care by Bloomberg Intelligence
Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody Drug Conjugates

Okay, now just back to, we'll come to Destiny Breast05 in a minute, but in DB11, you did say, and I think you explained very clearly at the analyst meeting that I think is freely available on your website for folks to listen to if they needed to, that although the comparator arm was a standard of care,

Vanguards of Health Care by Bloomberg Intelligence
Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody Drug Conjugates

It's not the only standard of care.

Vanguards of Health Care by Bloomberg Intelligence
Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody Drug Conjugates

And I think the explanation was also given that, don't forget, this trial was started even before COVID, right?

Vanguards of Health Care by Bloomberg Intelligence
Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody Drug Conjugates

And then you ended up in a situation where you, you know, so over time, of course, when you do these long trials, there is a potential for change in standard of care.

Vanguards of Health Care by Bloomberg Intelligence
Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody Drug Conjugates

How would we read that in terms of how sure are you if physicians wanted to use this with another standard

Vanguards of Health Care by Bloomberg Intelligence
Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody Drug Conjugates

combo, that they would get similar results?

Vanguards of Health Care by Bloomberg Intelligence
Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody Drug Conjugates

Or do you think there would have to be done, further trials have to be done?

Vanguards of Health Care by Bloomberg Intelligence
Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody Drug Conjugates

Okay, and then one last question on DB11 before we move on to DB05, and that is the ILD pneumonitis rates.

Vanguards of Health Care by Bloomberg Intelligence
Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody Drug Conjugates

ILD is one of the side effects of N HER2 and other HER2-targeting ADCs and even some other ADCs, I think.

Vanguards of Health Care by Bloomberg Intelligence
Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody Drug Conjugates

So, but you represented them as a combination.

Vanguards of Health Care by Bloomberg Intelligence
Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody Drug Conjugates

Now, ILD is a, if I'm not wrong, and you can correct me if I am wrong, is a relatively, has a risk of long-term consequences, whereas pneumonitis is maybe viewed as a more short-term issue.

Vanguards of Health Care by Bloomberg Intelligence
Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody Drug Conjugates

Was there much of a difference between the two?